Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II

Lancet

Volumn 355, Issue 9215, 2000, Pages 1582-1587

  Pitt, Bertram ^a   Poole Wilson, Philip A ^b   Segal, Robert ^c   Martinez, Felipe A ^d   Dickstein, Kenneth ^e   Camm, A John ^f   Konstam, Marvin A ^g   Riegger, Günter ^h   Klinger, George H ^c   Neaton, James ⁱ   Sharma, Divakar ^c   Thiyagarajan, Balasamy ^c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Fundacion Rusculleda   (Argentina)

^e STAVANGER UNIVERSITY HOSPITAL   (Norway)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^g TUFTS MEDICAL CENTER   (United States)

^h UNIVERSITY HOSPITAL REGENSBURG   (Germany)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HEART DEATH; HEART EJECTION FRACTION; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUDDEN DEATH; SURVIVAL TIME;

EID: 0034612118     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02213-3     Document Type: Article

References (38)

1. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995; 92: 2764-84.
2. Guidelines: the treatment of heart failure. Eur Heart J. 18:1997;736-753.
3. Cohn J.N. The management of chronic heart failure. N Engl J Med. 335:1996;490-498.
4. Hobbs F.D.R. Primary care physicians. champions of or an impediment to optimal care of the patient with heart failure? Eur J Heart Failure. 1:1999;11-15.
5. Houghton A.R., Cowley A.J. Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners? Int J Cardiol. 59:1997;7-10.
6. Brown N.J., Vaughan D.E. Angiotensin-converting enzyme inhibitors. Circulation. 97:1998;1411-1420.
7. Timmermans P.B.M.W.M., Wong P.C., Chiu A.T.et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 45:1993;205-251.
8. Rump L.C., Oberhauser V., Schwertfeger E., Schollmeyer P. Experimental evidence to support ELITE. Lancet. 351:1998;644-645.
9. Hatta E., Maruyama R., Marshall S.J., Imamura M., Levi R. Bradykinin promotes ischemic norepinephrine release in guinea pig and human hearts. J Pharmacol Exp Ther. 288:1999;919-927.
10. Goldberg A.I., Dunlay M.C., Sweet C.S. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 75:1995;793-795.
11. Lacourciere Y., Brunner H., Irwin R.et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens. 12:1994;1387-1393.
12. Urata H., Healy B., Stewart R.W.et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 66:1990;883-890.
13. Dzau V.J., Mukoyama M., Pratt R.E. Molecular biology of angiotensin II receptors. J Hypertens. 12:1994;1-5.
14. Pitt B., Segal R., Martinez F.A.et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet. 349:1997;747-752.
15. Pahor M., Gambassi G., Carbonin P. Antiarrhythmic effects of ACE inhibitors. a matter of faith or reality? Cardiovasc Res. 28:1994;173-182.
16. Pratt C.M., Gardner M., Pepine C.et al. Lack of long-term ventricular arrhythmia reduction by enalapril in heart failure. Am J Cardiol. 75:1995;1244-1249.
17. Thomas G.P., Ferrier G.R., Howlett S.E. Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion. J Pharm Exp Ther. 278:1996;1090-1097.
18. Lynch J.J., Stump G.L., Wallace A.A. EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction. J Am Coll Cardiol. 34:1999;876-884.
19. Brooksby P., Robinson P.J., Segal R.et al. Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. Lancet. 354:1999;395-396.
20. Pitt B., Poole-Wilson P., Segal R.et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline charactertistics of patients in the losartan heart failure survival study ELITE II. J Card Fail. 5:1999;146-154.
21. O'Brien P.C., Fleming T.R. A multiple testing procedure for clinical trials. Biometrics. 35:1979;549-556.
22. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet. 353:1999;2001-2007.
23. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). a randomised trial Lancet. 353:1999;9-13.
24. McDonald K.M., D'Aloia A., Parrish T.et al. Functional impact of an increase in ventricular mass after myocardial damage and its attenuation by converting enzyme inhibition. J Card Fail. 4:1998;203-212.
25. Dickstein K., Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design - Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol. 83:1999;477-481.
26. Swedberg K., Pfeffer M., Granger C.et al. Candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail. 5:1999;276-282.
27. Cohn J.N., Tognoni G., Glazer R.D., Spormann D., Hester A. Rationale and design of the Valsartan Heart Failure Trial. a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure J Card Fail. 5:1999;155-160.
28. Burnier M., Brunner H.R. Angiotensin II receptor antagonists. Lancet. 355:2000;637-645.
29. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 316:1987;1429-1435.
30. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 325:1991;293-302.
31. Garg R., Yusuf S. Overview of randomized trials of angiotensin converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 273:1995;1450-1456.
32. Gottleib S., Dickstein K., Fleck E.et al. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 88:1993;1602-1609.
33. Crozier I., Ikram H., Awan N.et al. Losartan in heart failure. hemodynamic effects and tolerability - Losartan Hemodynamic Study Group Circulation. 91:1995;691-697.
34. Lang R.M., Elkayam U., Yellen L.G.et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. J Am Coll Cardiol. 30:1997;983-991.
35. Dickstein K., Chang P., Willenheimer R.et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 26:1995;438-445.
36. Klinger G., Jaramillo N., Ikram H.et al. Effects of losartan on exercise capacity, morbidity and mortality in patients with symptomatic heart failure. J Am Coll Cardiol. 29:1997;205.
37. Davies M.K., Gibbs C.R., Lip G.Y.H. ABC of heart failure. management - diuretics, ACE inhibitors, and nitrates BMJ. 320:2000;428-431.
38. Adams K.F., Baugham K.L., Dec W.G.et al. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction: pharmacological approaches. J Card Fail. 5:1999;357-382.